CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1-4 in San Diego. Data on LEQEMBI® (lecanemab-irmb) will include findings on subcutaneous administration for initiation dosing, the benefits of continued therapy and estimated time savings over 10 years of treatment based on Phase 3 clinical data, and real-world experience from a post-marketing observational study in Japan and the ALZ-NET registry. The company will also share new insights into BIIB080, an investigational antisense oligonucleotide (ASO) therapy, from a healthy-volunteer biodistribution study, as well as research that helps inform understanding of disease progression.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
